Drug intelligence / Profile preview

platelet-rich plasma and fibrin clot (PRGF-System)

Development stage
Phase 2
Lead developer
BTI Biotechnology Institute
Modality
Cell Therapies
Administration
Intralesional
01

Overview

Platelet-rich plasma and fibrin clot processed with the PRGF-System (Plasma Rich in Growth Factors) is an autologous biologic therapy derived from the patient's own peripheral blood. Developed using proprietary technology from BTI Biotechnology Institute, the system concentrates platelets and growth factors to produce both a liquid platelet-rich plasma fraction and a polymerized fibrin clot. These components are applied intralesionally to promote tissue repair, wound healing, and local immunomodulation. The therapy is currently being investigated in Phase II clinical trials, notably by Fundación FISEVI in Spain, for the treatment of complex perianal fistulas in patients with Crohn's disease. Its mechanism of action involves the local release of endogenous growth factors, including PDGF, TGF-β, VEGF, and EGF, which stimulate cellular proliferation and extracellular matrix synthesis.

Brand names
PRGF-SystemEndoret
Other names
Plasma Rich in Growth FactorsPRGFautologous platelet-rich plasma and fibrin clot

Beyond the preview

Go deeper on platelet-rich plasma and fibrin clot (PRGF-System).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on platelet-rich plasma and fibrin clot (PRGF-System).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call